Evidence map›Paper›PMID 42834983›Full record

ArticleJournal of pharmaceutical analysis2026

Hong Jiang, Yongxiang Wang, Qimeng Tian, Yihang Sui, Jingge Sun, Ling Chen, Xiaoqiong Liu, Ninghua Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hong JiangDepartment of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Yongxiang WangKey Laboratory for Quality Control of Traditional Chinese Medicine of National, Administration of Traditional Chinese Medicine, Institute of Chinese Medicine, Jiangsu Longfengtang, Traditional Chinese Medicine Co. Ltd., Yangtze River Pharmaceutical Group, Taizhou, Jiangsu, 225300, China.
Qimeng TianDepartment of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Yihang SuiDepartment of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Jingge SunDepartment of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Ling ChenDepartment of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Xiaoqiong LiuDepartment of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Ninghua TanDepartment of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut microbiota dysbiosis is significantly associated with the onset and progression of cough variant asthma (CVA). Targeting and improving gut microbiota dysbiosis may serve as a promising strategy for CVA. Suhuang antitussive capsule (SH) is the sole clinically approved traditional Chinese patent medicine specifically indicated for managing CVA. Herein, we initially identified arctigenin (AG) as one of the effective components detected and preliminarily screened from SH for its potential in treating CVA. AG significantly ameliorates ovalbumin (OVA)-induced CVA symptoms, alleviates gut dysbiosis, and improves intestinal barrier function. Specifically, AG alleviates CVA symptoms in a gut microbiota-dependent manner, as demonstrated by antibiotic treatment and fecal microbiota transplantation (FMT). 16S rDNA sequencing revealed that AG treatment could notably enrich the commensal bacterium

Indexed as

ArctigeninBifidobacterium pseudolongumCough variant asthmaInterleukin-33Short-chain fatty acidsSuhuang antitussive capsule

Identifiers

PMID42834983
PMCPMC13634998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.